Skip to main content
Journal ArticleOPEN ACCESS

Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy

Cell Research (2018) 28(5) 501-502
DOI: 10.1038/S41422-018-0031-9
15Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A CTLA-4-specific antibody, ipilimumab, is clinically used in anticancer immunotherapy, yet induces severe autoimmune side effects. Two papers by Du et al. published recently in Cell Research now suggest strategies for potentially uncoupling toxicity and efficacy of CTLA-4-targeting antibodies.

Cite

CITATION STYLE

APA

Pol, J., & Kroemer, G. (2018). Anti-CTLA-4 immunotherapy: uncoupling toxicity and efficacy. Cell Research, 28(5), 501–502. https://doi.org/10.1038/S41422-018-0031-9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free